DIABETOLOGY / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Diabetic nephropathy (DN) is a leading cause of kidney failure. Lysozyme (LYZ) is an essential component of innate immunity and exhibits antibacterial properties. However, LYZ has been reported to induce nephropathy, implying a possible association between impaired renal function and lysozyme expression.

Material and methods:
Bioinformatics analysis was used to predict the hub gene associated with DN, and the differential expression of the hub gene was confirmed using a mouse model. A mouse model of streptozotocin (STZ)-induced diabetic nephropathy was established to investigate the correlation between DN and LYZ expression, and the functionality of LYZ was verified through knockdown and overexpression experiments conducted in vivo. Immunohistochemistry (IHC) was utilized to assess fibrosis-related markers and cytokines, while Masson staining was performed to assess renal fibrosis. Fibroblast proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay. The role of the JAK pathway was confirmed using the JAK inhibitor AG490, and Western blot was used to investigate the underlying mechanisms.

Results:
Mechanistically, 25 mM glucose promotes the expression of LYZ in fibroblastic cells, and LYZ may in turn promote the proliferation of renal interstitial fibroblasts. Western blot shows that glucose can activate STAT3 in an LYZ-dependent manner, and the JAK inhibitor AG490 can partially suppress LYZ-induced STAT3 activation. Furthermore, in vivo observations have revealed that overexpression of LYZ is associated with the senescent phenotype of renal tubular epithelial cells (RTECs).

Conclusions:
Lysozyme promotes kidney fibrosis via the JAK/STAT3 signaling pathway in diabetic nephropathy, and glucose may promote fibroblast proliferation by promoting LYZ auto-secretion.

 
REFERENCES (32)
1.
Qi C, Mao X, Zhang Z, et al. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res 2017; 2017: 8637138.
 
2.
Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, et al. Biomarkers of diabetic nephropathy: a 2017 update. Crit Rev Clin Labor Sci 2017; 54: 326-42.
 
3.
Ismail A, Abd El-Azeim A. Response of erectile dysfunction to extracorporeal shock wave therapy in type 2 diabetic men. Physiother Quarter 2022; 30: 77-80.
 
4.
Ismail A, Abdelghany A, Atef H. Response of testosterone and semen parameters to a 14-week aerobic training in sedentary obese men with hyperglycaemia. Physiother Quart 2023; 31: 28-33.
 
5.
Ismail AMA, El-Azeim ASA. Short-term intraocular pressure response to the combined effect of transcutaneous electrical nerve stimulation over acupoint (Acu-TENS) and yoga ocular exercise in type 2 diabetic patients with primary open-angle glaucoma: a randomized controlled trial. J Acupunct Meridian Stud 2021; 14: 193-9.
 
6.
Ismail A, Abd El-Azeim A. Immediate fasting blood glucose response to electroacupuncture of ST36 versus CV 12 in patients with type 2 diabetes mellitus: randomized controlled trial. Fam Med Prim Care Rev 2021; 23: 437-41.
 
7.
Khan NU, Lin J, Liu X, et al. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim Biophys Acta 2020; 1868: 140475.
 
8.
Kishore L, Kaur N, Singh R. Distinct biomarkers for early diagnosis of diabetic nephropathy. Curr Diab Rev 2017; 13: 598-605.
 
9.
Swaminathan R, Ravi VK, Kumar S, et al. Lysozyme: a model protein for amyloid research. In: Advances in Protein Chemistry and Structural Biology: Donev R (ed.). Academic Press 2011; 63-111.
 
10.
Liu J, Wang N, Liu Y, et al. The antimicrobial spectrum of lysozyme broadened by reductive modification. Poultry Sci 2018; 97: 3992-9.
 
11.
McCanna DJ, Oh S, Seo J, et al. The effect of denatured lysozyme on human corneal epithelial cells. Investig Ophthalmol Visual Sci 2018; 59: 2006-14.
 
12.
Lee W, Ku SK, Na DH, et al. Anti-inflammatory effects of lysozyme against HMGB1 in human endothelial cells and in mice. Inflammation 2015; 38: 1911-24.
 
13.
Bergamo A, Gerdol M, Pallavicini A, et al. Lysozyme-induced transcriptional regulation of TNF- pathway genes in cells of the monocyte lineage. Int J Mol Sci 2019; 20: 5502.
 
14.
Steinrauf LK, Shiuan D, Yang W, et al. Lysozyme association with nucleic acids. Biochem Biophys Res Commun 1999; 266: 366-70.
 
15.
Ismail A, Abdelhay M, Draz R. Response of salivary flow rate to transcutaneous electrical nerve stimulation in haemodialysis patients. Physiother Quart 2023; 31: 23-7.
 
16.
Liu Q, Liang X, Liang M, et al. Ellagic acid ameliorates renal ischemic-reperfusion injury through NOX4/JAK/STAT signaling pathway. Inflammation 2020; 43: 298-309.
 
17.
Wang X, Shaw S, Amiri F, et al. Inhibition of the JAK/STAT signaling pathway prevents the high glucose-induced increase in TGF- and fibronectin synthesis in mesangial cells. Diabetes 2002; 51: 3505.
 
18.
Shen YL, Jiang YP, Li XQ, et al. ErHuang formula improves renal fibrosis in diabetic nephropathy rats by inhibiting CXCL6/JAK/STAT3 signaling pathway. Front Pharmacol 2019; 10: 1596.
 
19.
Sun MY, Wang SJ, Li XQ, et al. CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway. Front Pharmacol 2019; 10: 224.
 
20.
Banes AK, Shaw S, Jenkins J, et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004; 286: F653-9.
 
21.
Yang F, Qin Y, Lv J, et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy. Cell Death Dis 2018; 9: 1000.
 
22.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease. Clin J Am Soc Nephrol 2017; 12: 2032.
 
23.
Rabkin R. Diabetic nephropathy. Clin Cornerstone 2003; 5: 1-11.
 
24.
Kobrin SM. Diabetic nephropathy. Disease-a-Month 1998; 44: 214-34.
 
25.
Ismail AMA, Abd Elfatah Abo Saif HF, El-Moatasem Mohamed AM. Effect of Jyoti-Trataka on intraocular pressure, autonomic control, and blood glucose in diabetic patients with high-tension primary open-angle glaucoma: a randomized-controlled trial. J Complement Integr Med 2022; 19: 1013-8.
 
26.
Lu Y, Liu D, Feng Q, et al. Diabetic nephropathy: perspective on extracellular vesicles. Front Immunol 2020; 11: 943.
 
27.
Furuichi K, Shimizu M, Hara A, et al. Diabetic nephropathy: a comparison of the clinical and pathological features between the CKD Risk classification and the classification of diabetic nephropathy 2014 in Japan. Intern Med 2018; 57: 3345-50.
 
28.
Fioretto P, Barzon I, Mauer M. Is diabetic nephropathy reversible? Diabetes Res Clin Pract 2014; 104: 323-8.
 
29.
Marrero MB, Banes-Berceli AK, Stern DM, et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F762-8.
 
30.
Malik S, Suchal K, Khan SI, et al. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-B-TNF- and TGF-1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol 2017; 313: F414-22.
 
31.
Voelker J, Berg PH, Sheetz M, et al. Anti-TGF-beta1 antibody therapy in patients with diabetic nephropathy. J Am Soc Nephrol 2017; 28: 953-62.
 
32.
Sonkodi S, Mogyorósi A. Treatment of diabetic nephropathy with angiotensin II blockers. Nephrol Dialysis Transpl 2003; 18 (Suppl 5): v21-3.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top